Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis DOI Open Access
Jubin Matloubieh,

David Hanelin,

Ilir Agalliu

и другие.

Cancers, Год журнала: 2024, Номер 16(24), С. 4125 - 4125

Опубликована: Дек. 10, 2024

Background: Non-muscle-invasive bladder cancer (NMIBC) comprises about 75% of all cancers. Although NMIBC is treatable, it poses significant costs and burdens to patients due high recurrence rates. We conducted an updated meta-analysis studies that evaluated the efficacy outcomes after treatment with mitomycin C (MMC), gemcitabine (GEM), docetaxel (DOCE) for progression. Methods: searched PubMed Cochrane databases observational cohort randomized clinical trials (RCT) between 2009 2022 assessed GEM, DOCE, or MMC, alone in combination, regarding outcomes. A total 49 met inclusion criteria were reviewed their quality, sample size, outcomes, potential bias, relevant data extracted meta-analysis. Separate meta-analyses performed assess risks progression when comparing GEM/DOCE MMC vs. other treatments. Study heterogeneity was by I2 statistics. Results: Among 31 GEM treatments recurrence, there statistically risk reductions 24% (pooled relative (RR) 0.76; 95% confidence interval (CI) 0.64–0.87) 37% RR = 0.63; CI 0.58–0.68). Recurrence-free survival (RFS) 69.5% (95% 66.6–72.3%) 67.2% 66.2–68.2%), respectively. Studies assessing combination had a pooled RFS 44.6% 40.4–48.7%). Fewer examined progression, large variability inconclusive results across them. Conclusions: Our findings corroborate recent guidelines indicating both are effective reduce tumor improve NMIBC, although studies. DOCE treatment, results. Women minorities generally underrepresented, raising concerns generalizability highlighting importance including broader patient population future RCTs.

Язык: Английский

Ranolazine Attenuates Mouse Detrusor Contractility: Evidence for the Involvement of Calcium-Related Mechanisms DOI
Elif Nur Barut, Seçkin Engin,

Gökçe Dağlar

и другие.

European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177377 - 177377

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Phenazopyridine Inhibits Bladder Mechanosensory Signalling via the Bladder Lumen DOI

Aaron Clark,

Georgia Bourlotos,

Mary Elmasri

и другие.

European Urology Open Science, Год журнала: 2025, Номер 76, С. 14 - 16

Опубликована: Апрель 26, 2025

Язык: Английский

Процитировано

0
Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome DOI Creative Commons
Wan‐Ru Yu, Jia‐Fong Jhang, Hann‐Chorng Kuo

и другие.

Toxins, Год журнала: 2024, Номер 16(2), С. 74 - 74

Опубликована: Фев. 1, 2024

Intravesical botulinum toxin A (BoNT-A) injections are included in the interstitial cystitis/bladder pain syndrome (IC/BPS) treatment guidelines. However, IC phenotype suitable for with BoNT-A has not been clarified. Therefore, we identified factors influencing outcomes intravesical patients non-Hunner IC/BPS (NHIC). This retrospective study NHIC who underwent 100 U over past two decades. Six months after treatment, were assessed using Global Response Assessment (GRA). Outcome endpoints GRA, clinical symptoms, urodynamic parameters, urine biomarkers, and identification of contributing to satisfactory outcomes. The 220 (42 men, 178 women). group (n = 96, 44%) had significantly higher severity scores symptoms index, larger maximum bladder capacity (MBC), lower 8-isoprostane levels at baseline. Logistic regression revealed that MBC (≥760 mL) predominance associated injection. Subjective parameters improved pain-predominant Thus, or pelvic more likely experience following injections.

Язык: Английский

Процитировано

3
Unraveling the complexity of bladder-centric chronic pain by intravesical contrast enhanced MRI DOI Creative Commons
Pradeep Tyagi, Jodi K. Maranchie, Rajiv Dhir

и другие.

Continence, Год журнала: 2023, Номер 7, С. 101041 - 101041

Опубликована: Июль 20, 2023

Bladder pain, a common symptom associated with various urological conditions, poses diagnostic challenge as existing imaging modalities fail to pinpoint the bladder definitive source of pain. While pain is often linked localized inflammation resulting from urinary tract infections (UTIs) or Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), which can be exacerbated by emotional stress, current urine-based markers cannot precisely identify specific site within tract, spanning kidneys urethral meatus. Cystoscopy, currently considered gold standard, recommended American Urological Association (AUA) prior aggressive treatment for IC/BPS patients, it confirms presence inflammation, particularly in Hunner lesions, and predicts higher response rate anti-inflammatory medication like cyclosporine. Nonetheless, invasiveness cystoscopy, relies on investigator expertise, coupled significant variability detecting underscores its limitations inflammatory phenotyping. These factors contribute reluctance choosing cystoscopy preferred method may also lack success observed clinical trials assessing efficacy novel drugs. Given that immune cell infiltration into sites tight junction dilatation, paracellular entry injected instilled paramagnetic dyes, mimicking extravasation colored dyes such Evans blue dye could robust index vascular urothelial hyperpermeability—a characteristic sign inflammation. This article aims delve pathophysiology bladder-centric chronic context challenging diagnosis explore pivotal role Stokesian Fickian diffusion evolution intravesical contrast-enhanced MRI (ICE-MRI) phenotyping tool transitioning laboratory research practical application.

Язык: Английский

Процитировано

4
Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration DOI Open Access
Pradeep Tyagi, Jason Hafron, Jonathan L. Kaufman

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(9), С. 4945 - 4945

Опубликована: Май 1, 2024

Bladder cancer (BC) presents a significant global health burden, characterized by high recurrence rates post-initial treatment. Gender differences in BC prevalence and response to therapy emphasize the importance of personalized treatment strategies. While Bacillus Calmette–Guérin (BCG) remains cornerstone therapy, resistance poses challenge, necessitating alternative Immune checkpoint inhibitors (ICIs) have shown promise, yet systemic toxicity raises concern. Intravesical administration ICIs offers potential solution, with recent studies demonstrating feasibility efficacy intravesical pembrolizumab. Although concern, its localized may mitigate adverse events. Additionally, liposomal delivery exhibits promises enhancing drug penetration reducing toxicity. Novel imaging modalities compatible Vesical Imaging-Reporting Data System (VI-RADS) capable predicting high-grade bladder can aid pre-operative shared decision making patient surgeon. Future research should focus on refining approaches, optimizing dosing regimens, leveraging advanced techniques improve outcomes. In conclusion, immunotherapy promising avenue for treatment, offering enhanced therapeutic effectiveness while minimizing Continued efforts are essential validate these findings optimize immunotherapy’s role management, ultimately improving

Язык: Английский

Процитировано

0
Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine, and Docetaxel for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis DOI Open Access
Jubin Matloubieh,

David Hanelin,

Ilir Agalliu

и другие.

Cancers, Год журнала: 2024, Номер 16(24), С. 4125 - 4125

Опубликована: Дек. 10, 2024

Background: Non-muscle-invasive bladder cancer (NMIBC) comprises about 75% of all cancers. Although NMIBC is treatable, it poses significant costs and burdens to patients due high recurrence rates. We conducted an updated meta-analysis studies that evaluated the efficacy outcomes after treatment with mitomycin C (MMC), gemcitabine (GEM), docetaxel (DOCE) for progression. Methods: searched PubMed Cochrane databases observational cohort randomized clinical trials (RCT) between 2009 2022 assessed GEM, DOCE, or MMC, alone in combination, regarding outcomes. A total 49 met inclusion criteria were reviewed their quality, sample size, outcomes, potential bias, relevant data extracted meta-analysis. Separate meta-analyses performed assess risks progression when comparing GEM/DOCE MMC vs. other treatments. Study heterogeneity was by I2 statistics. Results: Among 31 GEM treatments recurrence, there statistically risk reductions 24% (pooled relative (RR) 0.76; 95% confidence interval (CI) 0.64–0.87) 37% RR = 0.63; CI 0.58–0.68). Recurrence-free survival (RFS) 69.5% (95% 66.6–72.3%) 67.2% 66.2–68.2%), respectively. Studies assessing combination had a pooled RFS 44.6% 40.4–48.7%). Fewer examined progression, large variability inconclusive results across them. Conclusions: Our findings corroborate recent guidelines indicating both are effective reduce tumor improve NMIBC, although studies. DOCE treatment, results. Women minorities generally underrepresented, raising concerns generalizability highlighting importance including broader patient population future RCTs.

Язык: Английский

Процитировано

0